title: Linoleic acid enhances mitogen response and survival of septic weanling rats.
abstract: Immunologic responses to various dietary fats and concentrations remain controversial. The authors examined the effect of dietary omega-3 and omega-6 polyunsaturated fatty acids (PUFA) on the immune system of weanling rats. Male weanling Sprague-Dawley rats were fed special liquid diets based on a standard enteral formula: (I) control: 2.2% calories as safflower oil (linoleic acid), (II) omega-3: 2.2% calories as safflower oil and 30% calories as cod liver oil (linolenic acid), and (III) omega-6: 32.2% calories as safflower oil. Body weight and caloric intake were measured daily. Rats were fed special diets for 18 days, at which time they were subjected to either septic challenge with 2 x 10(3) colony forming units of Streptococcus pneumoniae (eight rats per diet group) or killed and a splenocyte mitogen assay performed (four rats per diet group). Supplementation with omega-6 resulted in prolonged survival after bacterial challenge (control, 30.5 +/- 0.5 hours; omega-3, 31.6 +/- 0.5; not significant; omega-6, 39.8 +/- 5.0; P < .05). A significant difference in mitogenic stimulation was seen with omega-3 and omega-6 in response to PHA (control, 10,856 +/- 3,342; omega-3, 14,605 +/- 3,042; P < .05; omega-6, 35,737 +/- 7,596; P < .05) and with omega-6 only in response to LPS (control, 3,543 +/- 1,083; omega-3, 8,777 +/- 1,269; omega-6, 10,101 +/- 3,008). Previous studies have suggested that diets high in omega-6 PUFA are immunosuppressive because of an increase in the production of the dienoic prostaglandins.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, University of Texas Medical School at Houston 77030.
authors.forename: R J
authors.initials: RJ
authors.lastname: Andrassy
authors.forename: R P
authors.initials: RP
authors.lastname: Pizzini
authors.forename: J G
authors.initials: JG
authors.lastname: Nirgiotis
authors.forename: P
authors.initials: P
authors.lastname: Hennessey
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001402:B-Lymphocytes / Q000187:drug effects; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology*; D002149:Energy Intake; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D007107:Immune System / Q000187:drug effects*; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008934:Mitogens / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000178:diet therapy / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D015996:Survival Rate; D014886:Weaning
chemical_list: D004042:Dietary Fats, Unsaturated; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D008070:Lipopolysaccharides; D008934:Mitogens; D010835:Phytohemagglutinins; D003208:Concanavalin A; D019787:Linoleic Acid